Document is current

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers

Crossref DOI link: https://doi.org/10.1186/s40661-017-0055-8

Published Online: 2017-11-29

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy